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ABSTRACT 
 
THE PROINFLAMMATORY EFFECT OF STRUCTURALLY ALTERED 










To further understand the effect of superimposed lung inflammation on COPD, 
our laboratory developed a hamster model of COPD exacerbations using 
sequential intratracheal instillations of lipopolysaccharide (LPS) and elastase. 
Using this model, the superimposed inflammatory effect of LPS on elastase- 
induced emphysema was studied through morphological and biochemical 
parameters. Total leukocyte and percent neutrophil count in bronchoalveolar 
lavage fluid (BALF), and elastin-specific desmosine crosslinks (DID) were 
measured 48 hours after LPS treatment. Morphometric changes were evaluated 
with mean linear intercept (MLI) methods, and interstitial elastic fiber and lung 
surface area measurements 1 week post-LPS treatment. Compared to controls, 
animals treated with elastase/LPS showed a significant increase in BALF 
leukocytes (187 vs 47.7 x 104 cells), neutrophils (39 vs 4.8 percent), and free 
DID levels (182 vs 97 percent). Additionally, MLI was significantly elevated in the 
elastase/LPS group compared to controls (156.2 vs 81.7micrometer). Due to 
enhanced splaying and fragmentation of elastic fibers, interstitial elastic fiber 
surface area was significantly increased in animals treated with elastase/LPS 
than controls (49 vs 26 percent). On the other hand, lung surface area was 
decreased in elastase/LPS group compared to controls (17.8 vs 25.5 percent). 
Furthermore, intratracheal instillations of elastin peptides and LPS demonstrated 
significant effects on BALF neutrophils, free DID levels and leukocyte 
chemotactic properties. The results suggest that structural alterations in elastic 
fibers during exacerbations make them more susceptible to breakdown and may 
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Chapter 1: INTRODUCTION 
 
Chronic obstructive pulmonary disease (COPD), characterized by progressive and 
irreversible airflow obstruction, exhibits the pathogenic features of emphysema, 
chronic bronchitis and/or asthma (1,2). Emphysema is characterized by gradual 
destruction of lung tissue, specifically thinning and elimination of alveolar walls 
with subsequent enlargement of air spaces (3). Chronic bronchitis is characterized 
by excess production of mucus by goblet cells increasing inflammation and 
obstruction of the airways (4). COPD is the third leading cause of death in the 
United States (5). Cigarette smoke is the primary cause of COPD with lifelong 
smokers having a 50% chance of developing the disease in their lifetime (6). 
Occupational exposure to dust, gases, fumes and silica can also cause COPD 
(7,8). Smoking cessation reduces the risk of COPD development by half (6). 
Smoke induces inflammatory responses in the lungs by recruiting oxidants, 
proteases and immune cells which contributes to expiratory airflow restriction (2). 
Smoke can also inhibit or alter the repair process of the lung parenchyma leading 
to destruction or fibrosis of the lung tissue, respectively (2). Tissue remodeling in 
small airways has also been detected in COPD patients (9). Additionally, 
persistent infiltration of inflammatory cells, including neutrophils, macrophages, 
T- and B- lymphocytes in the alveolar walls has been significantly associated with 
the severity of airflow obstruction based on Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) criteria (10). The link between small airway 





1.1 Acute Exacerbations 
 
 
Acute exacerbations of COPD (AECOPD) are defined by sudden aggravation of 
both respiratory and non-respiratory symptoms of COPD (11). Respiratory 
symptoms include cough, dyspnea and wheezing while non-respiratory symptoms 
include fatigue and malaise. Characteristics of AECOPD include 
bronchoconstriction, persistent cough, increased sputum production, and 
subsequent dyspnea (12,13). AECOPD have been associated with an accelerated 
decline in lung function and poorer prognosis in response to the increased 
inflammation in airways and lung parenchyma, especially in cases with mild 
COPD (14,15). The majority of episodes of AECOPD are initiated by a bacterial 
or viral respiratory infection, with non-typeable Hemophilus influenzae being the 
most common pathogen (13). They can also be caused by environmental air 
pollutants (16). The frequency of AECOPD episodes is increased as COPD 
progresses (17). The mechanisms underlying COPD exacerbations remains 
unknown (18). It is crucial to rule out congestive heart failure, pneumonia, and 
pulmonary emboli when COPD exacerbation is suspected (13). COPD 
exacerbations also accelerate the progression of emphysema, however, the 
underlying mechanisms leading to structural alterations in alveolar walls remains 
unknown (19). 
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1.2 Therapeutic Agents 
 
 
The progressive decline in lung function in COPD is poorly reversible since no 
therapeutic agents or procedures studied to date have been effective in slowing 
down the progression of the disease other than smoking cessation or occupational 
exposure discontinuation (20). Therefore, the main objective of pharmacological 
treatments available is to prevent or alleviate the symptoms, and decrease the 
frequency and severity of AECOPD (21). The most common anti-inflammatory 
agents used in COPD are corticosteroids (22). However, corticosteroids show 
poor efficacy in severe cases of COPD (23,24). Despite showing efficacy in 
exacerbations of COPD, glucocorticoids are generally not used in stable COPD 
due to their side effects and high costs (21). Additionally, corticosteroid resistance 
remains a challenging topic in treating severe COPD (22). Another centerpiece of 
COPD symptomatic treatment is bronchodilators including short-acting and long- 
acting 2-agonists, anticholinergic antimuscarinic agents, and theophylline (21). 




1.3 Elastic Fibers 
 
 
A major component of elastic fibers is elastin which plays a critical role in the 
biomechanics of the lungs permitting passive tissue recoil (elastic recoil) during 
expiration. These bundles of protein found in the extracellular matrix (ECM) of 
the connective tissue are mainly produced by fibroblasts, smooth muscle cells, 
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chondrocytes and endothelial cells (26). Elastases are a group of enzymes that 
break down elastic fibers and are produced in various locations, including 
pancreas, neutrophils, macrophages and platelets (26). Elastin degradation is a 
principal stage in the pathogenesis of COPD (27). Intratracheal (IT) instillation of 
elastase can promptly result in an approximate 40% loss of elastin in the lung 
mimicking emphysema (26,28). Enzymatic and oxidative breakdown of elastic 
fibers, producing elastin fragments, results in recruitment of inflammatory cells, 
including neutrophils, macrophages and lymphocytes to the lung which further 
aggravates elastic fiber degradation and loss of lung parenchyma and function 
(27). The main hypothesis for the development and progression of COPD and 
primarily emphysema is the protease-antiprotease imbalance (29). The protease- 
antiprotease imbalance theory has mainly been studied in patients with alpha-1 
antitrypsin deficiency who lack the alpha-1 antitrypsin, a neutrophil elastase 
inhibitor, leading to irreversible alveolar wall destruction and emphysema (30). 
Elastin degradation in COPD eventually contributes to loss of lung recoil causing 
a greater strain on alveolar walls (29). This mechanical failure in the interrelated 
lung parenchymal network leads to uneven distribution of forces in alveolar walls 
further deteriorating airspace enlargement and rupture (31). 
 
 
1.4 Desmosine and Isodesmosine 
 
 
Elastin cross-linking in the lung consists of two amino acids unique to mature 
elastin; desmosine and its isomer isodesmosine (DID) which can be used as a 
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biomarker of elastin degradation in COPD (32). DID are important diagnostic 
tools in evaluating the efficacy of drugs designed to decrease elastin degradation 
in COPD as they are reflective of enhanced elastic fiber turnover (32). Labib et al. 
reported an increased level of blood DID in stable COPD with a more enhanced 
elevation in AECOPD which determines greater lung destruction and further 
decline in lung function during exacerbations (33). Another study by Kim et al. 
found an association between urinary desmosine levels and the severity of 
emphysema (34). Recruitment and activation of inflammatory cells induced by 








Lipopolysaccharides (LPS), also known as endotoxins, are large molecules 
consisting of a lipid and polysaccharide with an O-antigen, and an outer and inner 
core. LPS which is found in the outer membrane of gram negative bacteria is 
present in cigarette smoke in considerable amounts as well as various 
occupational and environmental hazards (35,36). Inhaled LPS acts as a pro- 
inflammatory agent causing a surge in neutrophils, macrophages and cytokines in 
the sputum and bronchoalveolar lavage fluid, which can further lead to 
bronchoconstriction (37). 
Total leukocyte and neutrophil counts were significantly increased after inhalation 
of LPS in blood and sputum of healthy human subjects (38). Brass et al. observed 
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emphysematous changes in the lungs of experimental mice for up to 4 weeks after 
inhaling LPS which can be attributed to apoptosis (39). Furthermore, Lee et al. 
reported histopathological changes in the lungs as well as significant elevations in 
leukocyte and neutrophil counts in bronchoalveolar lavage fluid (BALF) of mice, 
48 hours after intranasal instillation of LPS (40). A single dose of IT LPS 
instillation in mice with elastase-induced emphysema mimics a human case of 
COPD exacerbation with more prominent alveolar destruction and inflammatory 
cell infiltration compared to elastase alone, LPS alone or control groups (18). 
Additionally, inhalation of nebulized LPS in guinea pigs resulted in inflammatory 
cells accumulation, goblet cell hyperplasia and alveolar enlargement in the lungs 
(41). Intranasal exposure to elastase and LPS in mice also led to decreased lung 
recoil, airway inflammation and obstruction, and goblet cell metaplasia (35). 
 
 
1.6 Elastin Peptides 
 
 
Elastin peptides (EP) in COPD patients are products of elastic fiber degradation 
by proteases, especially neutrophil proteases. Dupont et al. found that plasma 
concentrations of EP are elevated in stable COPD and twofold greater in COPD 
exacerbations. They also reported neutrophils to be unresponsive to EP which 
could be attributed to downregulation of elastin receptors of neutrophils during 
exacerbations (42). 
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1.7 Chemotaxis Assay 
 
 
Chemotaxis studies assess the ability of different cells to migrate towards a 
chemical concentration gradient. The chemotactic activity of neutrophils has 
shown to increase during acute exacerbations of COPD (43). Furthermore, Wu et 
al. demonstrated increased neutrophil chemotaxis towards sputum of COPD 
patients which was correlated with COPD progression (44). However, Yoshikawa 
et al. detected reduced chemotaxis of neutrophils in sputum of COPD patients 




1.8 Terminal Deoxynucleotide Transferase Mediated dUTP nick end labeling 
(TUNEL Assay) 
 
TUNEL assay is a procedure to detect apoptotic cells by identifying DNA 
fragmentation. An enzyme called terminal deoxynucleotide transferase catalyzes 
the attachment of dUTP nucleotides to the free 3'-hydroxyl termini of DNA 
breaks. Several studies have shown an increase in the apoptosis of the structural 
lung cells in COPD which may play a major role in the pathogenesis of the 
disease by correlating with alveolar destruction and airspace enlargement in 
emphysema (46–48). Additionally, apoptosis of neutrophils in COPD patients was 









The underlying mechanisms of the pathogenesis and progression of COPD 
exacerbations and the role of elastic fibers in this process are not well understood. 
In order to study the effect of superimposed inflammation on elastic fiber injury 
in COPD exacerbation, our laboratory developed a novel hamster model of COPD 
exacerbation by LPS instillation to enhance elastase-induced emphysema. 
Contrary to previous models, this one uses a minimum dose of elastase to develop 
emphysema followed by a single dose of IT LPS to stimulate superimposed 




1.10 Hypotheses and Specific Aims 
 
 
• Structural alterations in lung elastic fibers following elastase injury may 
increase their susceptibility to breakdown by secondary inflammation 
induced by LPS production. 
• Elastin peptides released by these structurally altered elastic fibers may 
intensify the adverse effects of COPD exacerbations. 
• Elastin degradation accompanying LPS infection may give rise to 
increased apoptosis and poorer outcomes of COPD exacerbations. 
Aim 1: To test the first hypothesis, we determined the effect of elastase 
pretreatment on LPS-induced infiltration of inflammatory cells into the lungs, 
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lung parenchymal destruction and elastic fiber injury. This was evaluated by 
measuring the following parameters: 
a) Total leukocyte count in BALF 
 
b) Percent neutrophil count in BALF 
 
c) Total and free DID content in BALF 
 
d) Total lung DID content 
 
e) Percent lung surface area 
 
f) Percent interstitial elastic fiber surface area 
 
g) Mean linear intercept 
 
h) Internal surface area 
 
Rationale: The number of leukocytes and neutrophils in BALF following LPS 
treatment demonstrates the extent of inflammation in the lungs which would help 
understand the complex pathogenesis of COPD exacerbations. 
BALF DID content indicates the amount of elastic fiber breakdown after LPS 
instillation and the subsequent levels of elastin peptides which could be useful for 
understanding the pathophysiology of elastin degeneration during COPD 
exacerbations. 
Lung surface area percentage is indicative of the extent of lung parenchymal 
destruction following LPS administration which may help describe why 
exacerbations are associated with a poorer prognosis of COPD. Interstitial elastic 
fiber surface area represents the amount of elastic fiber breakdown and the level 
of breakdown products (EP) in the lungs which may be helpful in explaining the 
progressive deterioration of lung function following exacerbations. 
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Aim 2: To test the second hypothesis, we assessed the effect of exogenously 
administered elastin peptides on LPS-induced infiltration of inflammatory cells 
into the lungs, lung parenchymal destruction and elastic fiber injury. This was 
evaluated by measuring the following parameters: 
a) Total leukocyte count in BALF 
 
b) Percent neutrophil count in BALF 
 
c) Total and free DID content in BALF 
 
Rationale: The number of inflammatory cells and neutrophils in the lungs after 
EP instillation would reveal whether these peptides have pro-inflammatory effects 
in the lungs which may lead to the irreversible aggravation of COPD symptoms 
following exacerbations. BALF DID levels indicate the degree of lung destruction 
after EP administration which may help explain the progressive decline in lung 
function following exacerbations. 
Aim 3: To further test the second hypothesis, we determined the effect of LPS 
and elastin peptides, separately and in combination, on the chemotactic activity of 
leukocytes from untreated animals in vitro. This was evaluated by performing 
chemotaxis assay to measure the relative fluorescence of leukocytes in presence 
of LPS and peptides. 
Rationale: The chemotactic activity of leukocytes towards a mixture of LPS and 
elastin peptides would be helpful in understanding exacerbations by showing 
whether structurally altered elastic fibers are responsible for the progression of the 
disease. 
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Aim 4: To test the third hypothesis, we determined the effect of elastase pre- 
treatment on LPS-induced apoptosis. This was evaluated by performing TUNEL 
assay to measure the number of apoptotic cells following treatment. 
Rationale: The number of apoptotic cells following elastase pretreatment may 
further elucidate the complex pathogenesis of COPD exacerbations and the 
possible interesting role of apoptosis in the irreversible lung damage following 
exacerbations. 
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2.1 Experimental Design 
 
 
The following experimental protocols were used to determine the 







Syrian female hamsters were divided into four groups and treated as follows: 
Group 1 received IT instillation of 1unit porcine pancreatic elastase (Elastin 
Products, Owensville, MO), followed by 100 µg LPS (Sigma-Aldrich, St Louis, 
MO) 1 week later; Group 2 received IT instillation of 1unit elastase, followed by 
IT normal saline (NS) 1 week later; Group 3 received IT NS, followed by 100 µg 
LPS 1 week later; Group 4 received two IT instillations of NS with a 1 week 
interval (controls). 
 
Morphometric measurements were made 1 week post-LPS treatment, including 
mean percent surface area of the lungs and interstitial elastic fibers, mean linear 
intercept (MLI) to determine airspace size, and internal surface area (ISA) per 
unit volume. Other measurements including, 1) total leukocyte count in BALF, 2) 
percent neutrophils in BALF 3) free and total BALF DID 4) total lung DID were 








In another set of experiments, Syrian female hamsters were divided into four 
groups and treated as follows: Group 1 received a combination of 100 µg IT LPS 
and 50 µg lung elastin peptides (Elastin Products, Owensville, MO); Group 2 
received 100 µg IT LPS alone; Group 3 was given 50 µg IT lung elastin peptides 
alone, and group 4 received IT NS alone. Measurements of 1) total leukocyte 
count in BALF 2) percent neutrophils in BALF 3) free and total BALF DID were 
made 48 hours after LPS and/or elastin peptides instillations. Additionally, 
chemotactic properties of elastin peptides and LPS (separately and combined) 





2.2 Materials and Methods 
 
 
2.2.1 Intratracheal Instillations 
 
 
Female Syrian hamsters, with an approximate weight of 100 g, were anesthetized 
using an intraperitoneal (IP) injection of ketamine and xylazine (Henry Schein 
Animal Health, Dublin, OH) with a dose of 150mg/kg and 10mg/kg, respectively. 
The animal was monitored for a minimum of 10 minutes to confirm anesthesia. 
They were then laid supine on a surgical board and restricted by elastic bands 
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across their limbs. The cervical area was disinfected with 70% alcohol and a 2 cm 
vertical incision was made through the skin, subcutaneous fat and muscle tissue. 
The trachea was exposed and a 1ml syringe with a 27-gauge needle (BD 
PrecisionGlide Needle), bent to facilitate insertion, was introduced into the 
trachea. Following insertion, 0.2 ml of NS containing the agents described in the 
experimental design were injected into the lungs. After instillation of the 
compound and withdrawal of the needle from the trachea, the incision site was 
closed using several metal clips and topical lidocaine gel was applied as a topical 
anesthetic to decrease pain and discomfort in the surgical area. The animals were 
observed for a minimum of an hour until consciousness was regained. All the 
animals were then returned to their respective cages and were allowed free access 




2.2.2 Collection of Bronchoalveolar Lavage Fluid and Lung Samples 
 
 
Animals were euthanized by CO2 asphyxiation. The lower thoracic area was then 
cleansed with 70% alcohol and surgically exposed to cut the diaphragm, ensuring 
complete lung collapse. An incision was made in the cervical area and two muscle 
layers (cleidomastoedus and digastricus) were split to expose the trachea. The 
trachea was cannulated with a 16-gauge needle (BD PrecisionGlide Needle) 
attached to a 5ml syringe. BALF was obtained by injecting and withdrawing 
phosphate-buffered saline (PBS) 3 times at 4, 3 and 3ml volumes to reach a final 
amount of 10ml for each animal. After lavage, lungs were removed from the chest 
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and separated from extrapulmonary structures, then stored at -20 degrees Celsius 




2.2.3 Analysis of BALF 
 
Total leukocyte counts were determined using a hemocytometer (Hausser 
Scientific ,Horsham, PA) at a magnification of 400x. The BALF was then 
centrifuged for 3 minutes at 5 shelves, the supernatant was removed and stored at 
-20 degrees Celsius for further analysis. Differential cell counts were performed 
by resuspension of the pellet in 1ml PBS, followed by plating of the cells onto 
microscopic slides with a cytocentrifuge (Shandon Inc., Pittsburgh, USA) for 5 
minutes at a speed of 1000 rpm. The slides were air dried, fixed in methanol for 5- 
7 minutes, treated with Giemsa stain, and coverslipped using Cytoseal. At least 
200 cells were identified using standard morphological criteria to determine 
percent neutrophil in BALF. 
 
 
2.2.4 Histological evaluation of lungs 
 
After euthanasia, the lungs were fixed with 10% neutral-buffered formalin for 2 
hours at a pressure of 20 cm H2O, then removed from the chest and immersed in 
formalin for 48 hours. Following removal of extrapulmonary structures, the 
samples were cut into random pieces and placed in cassettes for histological 
processing. The cassettes were passed through graded concentrations of ethanol, 
ranging from 35% to 100%, for 5 minute intervals, followed by repeated 
immersion in clean 100% xylene for 15, 25 and 40 minutes. The samples were 
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then sequentially incubated in xylene-paraffin mixture (1:1) for 1 hour, 100% 
paraffin for 1 hour and fresh 100% paraffin for 2 hours. They were finally 
embedded in blocks of paraffin wax, using a Leica 1160 tissue-embedding 
machine. The resulting tissue blocks were stored in a refrigerator prior to 
processing with a microtome. Tissue sections (5μm thickness) were cut with a 
standard rotary microtome (American Optical Company), floated in a water bath 
at 55 degrees Celsius, then layered on VectabondTM coated slides, and incubated 
at 55 degrees Celsius overnight for future studies. 
 
 
2.2.5 Hemotoxylin and Eosin Staining (H&E) 
 
Tissue sections were deparaffinized in three changes of xylene for 5 minutes each, 
then rehydrated in graded concentrations of ethyl alcohol(ETOH) (100%, 95%, 
70%, 30%) for 2 minute intervals, followed by washing in distilled water for 1 
minute. The sections were then stained with hematoxylin for 10 minutes, and 
sequentially immersed in distilled water for 2 minutes, ammonium chloride 
(NH4CL) and ETOH for 1 minute, tap and distilled water for 1 minute each, and 
70% ETOH for 2 minutes. The sections were then counterstained in eosin solution 
for 2 minutes and then dehydrated in alcohol as follows: 95% ETOH for 2 
minutes and 3 changes of 100% ETOH for 2 minutes each. Finally, sections were 
cleared in 3 changes of xylene 2 minutes each mounting with coverslips using 
permount. 
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2.2.6 Verhoeff’s Elastic Fiber Stain (VEG) 
 
Slide sections were deparaffinized in three changes of xylene for 5 minutes each, 
then rehydrated in distilled water for 1 minute. They were then stained in 
Verhoeff’s solution for 30 minutes. They were rinsed in 3 changes of tap water 
and differentiated in 2% ferric chloride solution for 2 minutes. At this step, black 
elastic fibers were observed microscopically on a grey background. The 
differentiation was stopped by washing the slides in a 2-3 changes of tap water. 
They were then treated in 5% sodium thiosulfate for 1 minute and washed in 
running tap water for 5 minutes. They were then counterstained in Van Gieson’s 
solution for 5 minutes, dehydrated quickly through 95% alcohol and 2 changes of 
100% alcohol, and cleared in 2 changes of xylene for 3 minutes each. Finally, 
they were coverslipped with mounting medium. 
 
 
2.2.7 Microscopic Studies 
 
The slides’ labels were covered and named randomly to avoid bias. The slides 
were then evaluated under light microscopy at 100x magnification with American 
Optics microscope. Photomicrographs of the slides were taken using Amscope 
MU1003 camera and ToupLite software to determine the percent surface area of 
both the lung and interstitial elastic fibers with ImageJ software. For each 
specimen, a minimum of 25 photomicrographs were captured and the results were 
demonstrated as the mean percentage of surface area at 100x magnification. 
Microscopic fields containing prominent blood vessels or airways were not 
included in the analyses. 
18  
Additionally, MLI was determined using a standard test grid over lung 
photomicrographs to count the number of intersections of alveolar walls with grid 
lines (50,51). Areas of hyperinflation or inadequate inflation were excluded. ISA 
per unit lung volume was measured using MLI values (52). 
 
 
2.2.8 Measurement of BALF DID 
 
Free and total BALF DID levels were measured using a combination of liquid 
chromatography and tandem mass spectrometry (LC/MS/MS). To measure free 
BALF DID levels, the supernatants previously collected and stored were 
concentrated to 0.5 ml and combined with 10% trifluoro-acetic acid to precipitate 
proteins. Following centrifugation, the samples were mixed with butanol, glacial 
acetic acid and water (4:1:1), then applied to a CF1 column, washed and eluted. 
For measuring total BALF DID levels, 2 ml of supernatants were mixed with an 
equal volume of 37% HCL and hydrolyzed at 110 degrees Celsius for 24 hour. 
The samples were then dried under vacuum, combined with 2 ml of butanol, 
glacial acetic acid and water (4:1:1), applied to a CF1 column, washed and eluted. 
Separation of the crosslinks was performed with a 2 × 100 mm dC18 column 
(Water Corporations, Milford, MA), using a combination of mobile phases: (A) 7 
mM heptafluorobutyric acid (HFBA) and 5 mM ammonium acetate in water, and 
B) 7 mM HFBA and 5 mM ammonium acetate in 80% acetonitrile. The BALF 
samples which had been filtered and dried following CF1 chromatography, were 
dissolved in mobile phase A and applied to the column. The elution gradient was 
performed linearly from 100 to 90% A over a 10-minute interval, and the 
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separated crosslinks were analyzed with a TSQ Discovery electrospray tandem 
mass spectrometer (Thermo Fisher Scientific, Waltham, MA), using selected 
reaction monitoring of mass to charge ratio transitions. The results were 
quantified by comparison with a d4-labeled desmosine standard. 
 
 
2.2.9 Measurement of Lung DID 
 
Whole lungs, free of extrapulmonary structures were washed to remove blood. 
They were then homogenized by ultrasonication and centrifuged. The supernatant 
was decanted and the pellet was resuspended in PBS and again centrifuged. This 
process was repeated twice and the remaining tissue was hydrolyzed in 37% HCL 
at 110 degrees Celsius for 24 hours. Total lung DID levels were then determined 
following the steps described above. 
 
 
2.2.10 Chemotaxis Assay 
 
BALF leukocytes from untreated animals were centrifuged and suspended in 
Dulbecco’s culture medium. They were gently mixed to ensure uniformity and 
placed in the upper wells of Boyden chambers with a 3 µm pore size membrane 
(Sigma-Aldrich, ST Louis, MO) and exposed to either: 1) 100 µg of elastin 
peptides and 10 µg LPS 2) 100 µg elastin peptides alone 3) 10 µg LPS alone, or 
4) neither elastin peptides nor LPS (controls) in the lower wells. The lower wells 
were filled with additional media to cover base of the upper wells. The same 
volume of media was used for each well. Additional chambers only contained 
culture medium in both upper and lower wells and were used for background 
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measurements. Following incubation at 37 degrees Celsius for 24 hours, cells 
were carefully removed from the top side of the insert. The contents of the lower 
wells were gently mixed to evenly distribute the cells. Cell migration through the 
membrane was determined with a CyQuant® cell assay kit (Thermo Fisher, 
Waltham, MA) which uses a fluorescent dye that binds to DNA. The treated cells 
were transferred to a 96-well microplate and a combination of fluorescent dye 
solution and lysis buffer was added to each well. The samples were incubated at 
room temperature for 15 minutes and fluorescence emission was measured with a 
fluorescent plate reader using a 480/520 nm filter set. 
 
 
2.2.11 Detection and quantification of apoptotic cells by terminal 
deoxynucleotide transferase mediated dUTP nick end labeling (TUNEL) 
assay 
The focal in situ apoptosis at the level of the pulmonary alveolar epithelium was 
determined using a terminal deoxynucleotide transferase mediated dUTP nick end 
labeling (TUNEL) kit (Chemicon International Inc, USA) on the paraffin- 
embedded sections of the lung samples according to the manufacturer’s protocol. 
The slides were deparaffinized in xylene three times for 5 minutes each, followed 
by rinsing in 2 changes of 100% ETOH for 5 minutes each, one change of 95% 
and one change of 70% ETOH for 3 minutes each, and in one change of PBS for 5 
minutes. They were then incubated in proteinase K (20 µg/mL) for 15 minutes at 
room temperature in a coplin jar. After washing the samples twice with distilled 
water for 2 minutes each, the slides were quenched with 3% hydrogen peroxide in 
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PBS for 5 minutes at room temperature, again washed twice with PBS for 5 
minutes each. The excess liquid on the slides was blotted and 75 µL/5cm2 of 
equilibration buffer was directly applied on the slides for 30 seconds. The excess 
liquid on the sample slides was blotted and this time 55 µL/5cm2 of working 
strength TdT enzyme was added to the slides and incubated in a humified 
chamber at 37 degrees Celsius for 1 hour. 
The reaction was then terminated by application of stop buffer, being agitated for 
15 seconds followed by incubation at room temperature for 10 minutes. The 
specimens were then washed in three changes of PBS for 1 minute each. After 
blotting the excess liquid, 65 µL/5 cm2 of room temperature anti-digoxigenin 
conjugate was applied directly on the slides and incubated in a humidified 
chamber for 30 minutes at room temperature. The slides were then washed in four 
changes of PBS for 2 minutes each. After blotting the excess liquid, 75 µL/5 cm2 
of peroxidase substrate was applied to cover the entire slide. They were then 
stained for 6 minutes at room temperature. 
After staining, the specimens were washed in 3 changes of distilled water for 1 
minute each and incubated in distilled water in a coplin jar for 5 minutes at room 
temperature. The slides were then counterstained in 0.5% methyl green for 10 
minutes at room temperature, washed in three changes of distilled water in a 
coplin jar, dipping the slides 10 times each in the first and second washes, 
followed by 30 seconds without agitation in the third wash. The slides were then 
washed in three changes of 100% n-butanol in a coplin jar following the same 
protocol as distilled water. The specimens were then dehydrated by using three 
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changes of xylene for 2 minutes each and mounted with coverslip using 
permount. 
TUNEL positive apoptotic cells were identified as brown stained cells under 400x 




2.2.12 Statistical Analysis 
 
One-way analysis of variance (ANOVA) and Bonferroni post-hoc test were used 
to determine statistically significant differences among treatment groups. A p- 
value of less than 0.05 was considered statistically significant. Results were 




Chapter 3: Results 
 
 
3.1 BALF Total Leukocyte Count 
 
 
Bronchoalveolar lavage was performed 48 hours after LPS administration. 
Animals treated with elastase/LPS had a significant increase in the number of 
BALF leukocytes (187 x 104) compared to elastase alone (37.3 x 104; p<0.0001), 










BALF neutrophils were significantly increased in the elastase/LPS group (39 
percent) compared to the elastase alone (3.4 percent; p<0.0001), LPS alone (14 




3.3 Lung Surface Area Measurements 
 
 
Determination of mean percent surface area of the lungs was performed 7 days 
post-LPS treatment. Animals receiving elastase/LPS had a significantly decreased 
percentage surface area compared to controls receiving saline alone (17.8 vs 25.5 
percent; p<0.0001). Those given elastase or LPS alone also had a significant 
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decrease in the percent surface area compared to controls (19.7 percent and 20.1 
percent, respectively, p,0.001), however this reduction was less prominent 




3.4 Elastic Fiber Surface Area 
 
 
Measurements of elastic fiber surface area (as a percentage of total surface area) 
were made 7 days after LPS-treatment. Elastic fiber surface area was significantly 
increased in the elastase/LPS group compared to LPS only and controls (49 vs 40 
and 26 percent, respectively). Elastase and LPS only groups also showed a 
significant elevation in elastic fiber surface area compared to controls (45 and 40 
vs 26 percent, respectively) (Figure 5). 
 
Animals treated with elastase/LPS showed more prominent splaying and 
fragmentation of lung elastic fibers due to increased lung elastin degradation. Less 
noticeable but similar changes were observed in the LPS and elastase only groups. 
The increase in the elastic fiber surface area can partly be explained by the 
structural alterations in elastic fibers (Figure 6). 
 
3.5 Mean Linear Intercept and Internal Surface Area 
 
 
Measurements of MLI and ISA was performed 7 days post-LPS treatment. 
Animals treated with elastase/LPS showed a significant increase in MLI (156.2 
m; p<0.0001) compared to those receiving LPS (98.0), elastase (85.5), and 
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controls (81.7). Additionally, the elastase/LPS group showed a significant 
decrease in ISA (25.7 mm2 per mm3 lung volume; p<0.0001) compared to the 






3.6 Total and Free BALF DID 
 
 
Measurements of free and total BALF DID levels were performed 48 hours post- 
LPS treatment. Free BALF DID levels were significantly higher in the 
elastase/LPS group compared to the elastase only group (182 vs 97 percent of 
control; p<0.05), however, the LPS only group did not show a significant 
difference from the elastase only group (Figure 8). 
 
Higher levels of total BALF DID was also noticed in the elastase/LPS group 
compared to the LPS and elastase only groups with no statistical significance 
(Figure 9). Previous studies in our laboratory have also identified free DID levels 





3.7 Total Lung DID 
 
 
Measurements of total lung DID were made 48hours post- LPS treatment. 
Animals treated with elastase/ LPS or elastase only demonstrated an increase in 
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total lung DID levels compared to controls although not significant (288 and 312 




3.8 Effects of Exogenous Elastin Peptides on BALF Cell Count and BALF 
DID 
 
Lungs treated with LPS and elastin peptides showed a significant increase in 
percentage of BALF neutrophils compared to those treated with LPS or peptides 
alone (37 vs 10 and 1.2 percent, respectively; p<0.0001) (Figure 12). However, 
total BALF leukocyte values were not significantly different between the groups 
(Figure 11). 
 
Measurements of free and total BALF DID were made 48 hours after LPS and/or 
elastin peptides treatment. Animals treated with both LPS and peptides had a 
significant increase in free BALF DID levels (as a percentage of control) 
compared to those given peptides alone and controls (330 vs 133 percent; p<0.05 
and 330 vs 100; p<0.01). However, there was no statistical significance between 
the LPS and peptide only groups (Figure 13). 
 
Total BALF DID levels were also increased in animals treated with LPS and 
elastin peptides with no statistical significance compared to other groups (Figure 
14). 
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3.9 Chemotaxis Assay 
 
 
The chemotactic activity of BALF leukocytes was determined in animals treated 
with LPS and elastin peptides, peptides alone, LPS alone and controls. 
Differential cell counts consisted of 98  1.5 percent macrophages in the LPS and 
peptide group. Chemotaxis was significantly increased in animals treated with 
peptides alone and LPS alone compared to controls (145 and 109 vs 12 relative 
fluorescence units  104 cells, respectively). However, treatment with LPS and 
elastin peptides resulted in a much greater chemotactic activity compared to 




3.10 TUNEL Assay 
 
 
Apoptosis of lung cells was measured in lung samples of the elastase/LPS, 
elastase only and control groups. TUNEL positive cells were significantly higher 
in the elastase/LPS group compared to both elastase and control groups (13.28 vs 
4.88 and 3.20 per HPF; p<0.0001) (Figure 16). 
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Chapter 4 : DISCUSSION 
 
 
4.1 COPD Exacerbations 
 
 
COPD exacerbations are defined as acute worsening of symptoms, including 
dyspnea, cough, sputum production and purulence (54). Exacerbation episodes are 
very common and the most important risk factor is previous history of 
exacerbations (55). Acute exacerbations are known to accelerate the progressive 
decline in lung function which is the main characteristic of COPD (56). The vast 
majority of COPD exacerbations are induced by bacterial or viral respiratory 
infections with non-typeable Hemophilus Influenzae considered the most 
prevalent pathogen (13). Additionally, around 30% of exacerbations are caused by 
environmental pollution or unknown etiologies (13). The presence of other 
comorbidities, especially congestive heart failure and pneumonia not only further 
complicates exacerbations but also makes it more difficult to determine the cause 




4.2 Management of COPD Exacerbations 
 
 
The major goal of management of COPD exacerbations is to reduce the severity 
and frequency of exacerbation episodes (21). The most common pharmacological 
treatments used for exacerbations are corticosteroids, bronchodilators, and 
antibiotics. Systemic corticosteroids have been long used for treating 
exacerbations of COPD due to their anti-inflammatory effects (12). However, 
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their use in the treatment of exacerbations has been controversial as they have 
sometimes failed to treat acute and severe episodes of exacerbations (57). 
Additionally, corticosteroids have been a less desirable option for treatment of 
stable COPD due to their adverse effects and high costs (21). Bronchodilators are 
the most common pharmacological treatment used in COPD which include short- 
and long-acting 2 agonists, anticholinergic antimuscarinic agents, and 
theophylline . Short-acting 2 agonists such as albuterol and antimuscarinic 
agents like ipratropium bromide are most commonly used during exacerbations. 
On the other hand, long-acting 2 agonists such as salmeterol are mostly used for 
treatment of stable COPD (13). Theophylline is a methylxanthine which has both 
bronchodilatory and anti-inflammatory effects but its use in early treatment of 
exacerbations is questionable due to many serious side effects and limited 
efficacy in improving lung function (58). 
 
The prophylactic use of antibiotics for COPD exacerbations has also been 
controversial as MacNee et al. proved them to be ineffective in reducing the 
frequency of episodes (59). On the other hand, Ko et al. stated that prophylactic 
use of antibiotics, especially macrolides has proved to decrease the frequency of 
COPD exacerbations due to the more prevalent infectious etiology of 
exacerbations(12). 
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4.3 Effect of Lung Remodeling on progression of COPD 
 
 
The biomechanics and interplay between the components of lung tissue and ECM 
are of significant importance in lung parenchymal injuries and subsequent tissue 
repair (60,61). Lung repair and remodeling processes further deteriorate airspace 
enlargement and airway obstruction, as prominent hallmarks of emphysema, due 
to disruption in mechanical forces, and loss of elastic recoil causing greater strain 
on alveolar walls (62,63). This rise in airspace pressure contributes to more 
prevalent alveolar destruction and rupture as elastic fiber degradation progresses 
(64). Additionally, there is some evidence that impaired resynthesis of elastin may 
play a major role in the pathogenesis of COPD. Although elastic fiber 
regeneration can partially restore the elastin content of airspaces, it does not 





4.4 Inflammatory Cells and Exacerbations 
 
 
Inflammation is regarded as a major characteristic of COPD with an increased 
level of neutrophils, lymphocytes and eosinophils detected in the lungs during 
exacerbations (66). Neutrophil elastase and myeloperoxidase enhance the 
inflammatory response in the lungs during exacerbations, induce oxidative stress 
and damage the important crosslinks in the ECM of the lungs. Although anti- 
inflammatory agents have been used in the treatment of COPD exacerbations, it is 
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important to investigate therapies that specifically target neutrophil recruitment 
and activation, and could potentially inhibit release of neutrophil elastase (67). 
Therefore, further studies are required to fully understand the inflammatory 
pathways involved in exacerbations to develop more effective treatment strategies 




4.5 DID Crosslinks in COPD 
 
 
DID crosslinks are an integral part of elastic fibers and their level in body fluids, 
including blood, sputum or urine can determine the progression and severity of 
COPD (68,69). The level of these lysyl-derived tetrafunctional amino acids in 
blood or sputum may be useful in assessing the efficacy of treatment in COPD as 
they reflect elastic fiber turnover in emphysema (32,70). 
 
Significantly increased levels of free BALF DID in animals treated with both 
elastase and LPS suggest that superimposed inflammation accelerates degradation 
of structurally altered elastic fibers in COPD exacerbations. This is consistent 
with enhanced splaying and fragmentation of elastic fibers observed in the 
elastase/LPS group in this study. The unraveling of these fibers make them more 
susceptible to enzymatic and oxidative breakdown by either loss of DID 
crosslinks or defective repair mechanisms to regenerate them, leading to further 
airspace enlargement and rupture. This phenomenon can contribute to the 
progressive decline in lung function known to occur during COPD exacerbations. 
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Upregulation of elastin resynthesis after breakdown of DID crosslinks may be 
helpful in treating COPD exacerbations or reducing their frequency. Joddar et al. 
showed that vascular smooth muscle cells can exhibit elastogenic effects when 
exposed to hyaluronan (HA) oligomers (71). 
 
Total lung DID content was not elevated in the elastase/LPS group in contrast to 
free BALF DID. This is consistent with findings of Deslee et al. who 
demonstrated no increase in lung desmosine content in severe COPD despite a 





4.6 Percent Lung and Elastic Fiber Surface Area 
 
 
Our results demonstrated that percent lung surface area was significantly 
decreased in the elastase/LPS group. This signifies the widespread lung 
parenchymal destruction during COPD exacerbations which occurs as a result of 
the complicated and yet not fully known pathophysiology of the disease. 
Regeneration and repair of the lung alveoli may be beneficial in preventing 
further lung destruction in exacerbations. The possible role of stem cell therapy in 
COPD to restore the intricate architecture of lung airspaces has been an 
interesting topic with clinical trials reporting minimal to no improvement in lung 
function after administration of these cells (73). Additional larger scale clinical 
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trials are needed to further explore this potential advanced treatment approach for 
COPD and exacerbations. 
 
Deslee et al. showed that elastin expression is considerably elevated in stage 4 
COPD indicating the potential role of an enhanced alveolar repair mechanism in 
very severe COPD (72). Introducing cells that either replace the lost pneumocytes 
in COPD, or proliferate and differentiate into the damaged tissue could represent 
a major advancement in the treatment of COPD exacerbations through alveolar 
regeneration (74). As current therapies for COPD exacerbations are palliative and 
the only permanent treatment strategy to prevent further lung deterioration is 
transplantation, further studies should investigate the potential benefits of 




4.7 Elastin Peptides and Exacerbations 
 
 
We determined that elastin peptides as products of elastic fiber breakdown act as 
chemo-attractants for inflammatory cells causing an influx of neutrophils into the 
lungs in response to LPS. This indicates that the more prominent and progressive 
structural and functional lung deterioration during COPD exacerbations is due to 
an enhanced level of elastin peptides in the alveoli. These findings are consistent 
with in vitro studies showing elastin fragments to intensify the inflammatory 
response in emphysema by attracting leukocytes into the lungs (75,76). 
Additionally, intratracheal instillations of EP in mice resulted in emphysematous 
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changes as well as inflammatory cell accumulation in the lungs (77). Another 
study found that despite smoking cessation, the number of inflammatory cells in 
airspaces remained the same (78). This persistent inflammation in COPD and 
specifically emphysema has been described as an autoimmune-mediated process 
supporting the theory that COPD mimics autoimmune disorders (79). As a result, 
COPD exacerbations may resemble the flare-ups experienced in autoimmune 
diseases enhancing elastolysis. This is an interesting area for future research to 
investigate the use of immunosuppressive drugs for COPD exacerbations. 
 
The significant elevation in BALF DID levels in LPS/peptides group suggests the 
important role of these fibers in the prognosis of exacerbations. Introducing 
agents that can either inhibit elastic fiber breakdown or remove elastin peptides 
may prevent the progressive decline in lung function during exacerbations. For 
instance, aerosolized HA has shown to decrease airspace enlargement in 
emphysema by preferentially binding to elastic fibers in both in vitro and vivo 
models (80,81). In a pilot clinical trial, plasma and sputum levels of DID were 
substantially reduced in COPD patients who used aerosolized HA for a 3-week 
period (82). Further studies are required to explore other potential 
pharmacological agents to prevent elastic fiber degeneration or remove elastin 
peptides in COPD exacerbations. 
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4.8 Role of Chemotaxis in Exacerbations 
 
 
Our results indicated a significant increase in the chemotactic activity of 
leukocytes in vitro when exposed to LPS/peptides compared to all other groups. 
Increased chemotaxis of leukocytes has previously been reported in COPD 
patients (43,44,83) .These findings are crucial in understanding the pathogenesis 
of COPD exacerbations as they support the theory that elastic fiber breakdown 
products display pro-inflammatory effects in the course of exacerbations which 
could enhance the influx of inflammatory cells, especially neutrophils into the 
lungs. This elevated inflammatory response will accelerate lung destruction and 
airspace enlargement which are characteristic of exacerbations. Therefore, the 
potential effect of chemotaxis antagonists like LTB4 inhibitors should be 
investigated in prevention and treatment of COPD exacerbations through 




4.9 Role of Apoptosis in Exacerbations 
 
 
Our results demonstrated a significant increase in the number of apoptotic cells in 
the elastase/LPS group. Increased apoptosis in the lungs of COPD patients was 
first reported in a study by Segura-Valdez et al. in which they showed a 
significant elevation in endothelial and epithelial cell death in lung tissues of 
COPD patients (46). Additionally, Markis et al. detected a significant increase in 
the number of apoptotic neutrophils in COPD patients which may had been 
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caused by either an impairment in the apoptotic mechanisms or decreased 
clearance of apoptotic cells from the lungs (49).Therefore, different apoptotic 
pathways are activated in COPD patients which explains the progressive 
deterioration in lung function even after smoking cessation (84). Furthermore, an 
imbalance between pro- and anti-apoptotic factors was indicated in COPD 
patients supporting the role of apoptosis in the intricated pathogenesis of the 
disease. As a result, restoring this imbalance and inhibiting apoptosis in the lungs 







Structural alterations in elastic fibers during exacerbations make them more 
susceptible to degradation and enhance the release of pro-inflammatory cells. 
Elastic fiber breakdown products (elastin peptides) further augment the 
inflammatory response in the lungs. These mechanisms result in increased 
alveolar destruction and airspace enlargement which further enhances the 
progression of the disease. Understanding the pathogenesis of COPD 
exacerbations and the complex interplay between different mechanisms, including 
protease-antiprotease imbalance, apoptosis, oxidative stress, and the pro- 
inflammatory effect of elastin peptides, may lead to more effective approaches to 











Group Control Elastase LPS Elastase + 
 
LPS 





81.7  2.9 
 
85.5  1.0 
 
98.0a  2.1 
 






49.4  1.8 
 
46.8  0.6 
 
40.9c  0.9 
 
25.7b  0.8 
 
 
Table showing mean linear intercept and internal surface area values. Results 
were expressed as mean ± SEM. Comparison among groups was done using one- 
way ANOVA followed by Bonferroni multiple comparison post-hoc test. 















Graph showing the total BALF leukocyte counts. The animals were treated with 
either IT elastase/LPS, elastase, LPS, or NS (control). The animals were euthanized 
48 hours after IT treatment. Results were expressed as mean ± SEM. Comparison 
among groups was done using one-way ANOVA followed by Bonferroni multiple 









Graph showing the percent BALF neutrophil content. The animals were treated 
with either IT elastase/LPS, elastase, LPS, or NS (control). The animals were 
euthanized 48 hours after IT treatment. Results were expressed as mean ± SEM. 
Comparison among groups was done using one-way ANOVA followed by 









Graph showing the percent lung surface area. The animals were treated with 
either IT elastase/LPS, elastase, LPS, or NS (control). The animals were 
euthanized 7 days after IT treatment. Results were expressed as mean ± SEM. 
Comparison among groups was done using one-way ANOVA followed by 




Hemotoxylin and eosin staining of paraffin sections of the lungs 
 
Photomicrograph of paraffin sections from hamster lungs stained with 
hemotoxylin and eosin. Upper left photomicrograph represents the lung of an 
animal treated with IT NS. The upper right photomicrograph represents the lung 
of an animal treated with IT LPS. The lower left photomicrograph represents the 
lung of an animal treated with IT elastase. The lower right photomicrograph 
represents the lung of an animal treated with IT elastase/LPS. The animals were 











Graph showing the percent interstitial elastic surface area. The animals were 
treated with either IT elastase/LPS, elastase, LPS, or NS (control). The animals 
were euthanized 7 days after IT treatment. Results were expressed as mean ± 
SEM. Comparison among groups was done using one-way ANOVA followed by 










Photomicrograph of elastic fiber of the lung of an animal treated with 
elastase/LPS showing areas of structural alterations in elastic fibers, including 










Graph showing mean linear intercept values. The animals were treated with either 
IT elastase/LPS, LPS, elastase, or NS (control). The animals were euthanized 7 
days after IT treatment. Results were expressed as mean ± SEM. Comparison 
among groups was done using one-way ANOVA followed by Bonferroni multiple 








Graph showing the free BALF DID content. The animals were treated with either 
IT elastase/LPS, LPS, elastase, or NS (control). The animals were euthanized 48 
hours after IT treatment. Results were expressed as mean ± SEM. Comparison 
among groups was done using one-way ANOVA followed by Bonferroni multiple 








Graph showing the total BALF DID content. The animals were treated with either 
IT elastase/LPS, LPS, elastase, or NS (control). The animals were euthanized 48 
hours after IT treatment. Results were expressed as mean ± SEM. Comparison 
among groups was done using one-way ANOVA followed by Bonferroni multiple 




















Graph showing the total lung DID content. The animals were treated with either 
IT elastase/LPS, elastase, or NS (control). The animals were euthanized 48 hours 
after IT treatment. Results were expressed as mean ± SEM. Comparison among 
groups was done using one-way ANOVA followed by Bonferroni multiple 








Graph showing the total BALF leukocyte counts. The animals were treated with 
either IT peptides/LPS, peptides, LPS, or NS (control). The animals were 
euthanized 48 hours after IT treatment. Results were expressed as mean ± SEM. 
Comparison among groups was done using one-way ANOVA followed by 








Graph showing the percent BALF neutrophil content. The animals were treated 
with either IT peptides/LPS, peptides, LPS, or NS (control). The animals were 
euthanized 48 hours after IT treatment. Results were expressed as mean ± SEM. 
Comparison among groups was done using one-way ANOVA followed by 









Graph showing the free BALF DID content. The animals were treated with either 
IT peptides/LPS, LPS, peptides, or NS (control). The animals were euthanized 48 
hours after IT treatment. Results were expressed as mean ± SEM. Comparison 
among groups was done using one-way ANOVA followed by Bonferroni multiple 









Graph showing the total BALF DID content. The animals were treated with either 
IT peptides/LPS, LPS, peptides, or NS (control). The animals were euthanized 48 
hours after IT treatment. Results were expressed as mean ± SEM. Comparison 
among groups was done using one-way ANOVA followed by Bonferroni multiple 






Graph showing chemotaxis assay results. BALF leukocytes from untreated 
animals were exposed to either peptides/LPS, peptides, LPS, or NS (control) in a 
Boyden chamber (chemotaxis) assay. Relative fluorescence emission of 
leukocytes were measured at a fluorescent plate reader using a 480/520 nm filter 
set. Results were expressed as mean ± SEM. Comparison among groups was done 







Graph showing TUNEL assay results. Paraffin sections of the lungs of animals 
treated with either IT elastase/LPS, elastase, or NS (control) were evaluated to 
detect and quantify apoptotic cells by terminal deoxynucleotide transferase 
mediated dUTP nick end labeling (TUNEL) assay. Number of brown-stained 
apoptotic cells were counted at magnification of 400x. Results were expressed as 
mean ± SEM. Comparison among groups was done using one-way ANOVA 
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